Trial reportJournal of neuro-oncology2019
Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.
Trial report in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.Journal of neuro-oncology · 2024Pooled it
- Review
- Prognostic associations of steroid use in patients with glioblastoma: A population-based study.Neuro-oncology practice · 2026Article
- The immunosuppressive tumor microenvironment in glioblastoma.Frontiers in immunology · 2026Review
- Antisecretory factor for treatment of peritumoral edema in glioblastoma patients.Acta neurochirurgica · 2025Article
- Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825.Neuro-oncology · 2025Article
- Review
- The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.Frontiers in immunology · 2024Review
- Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.Frontiers in immunology · 2024Review
- Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.BMC neurology · 2023Article
- Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma.Science translational medicine · 2023Article
- A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas.South Asian journal of cancer · 2022Article
- DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival.Nature communications · 2022Article
- COVID-19 and corticosteroids: a narrative review.Inflammopharmacology · 2022Review
- Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients.Neuro-oncology practice · 2021Article
- Review
- Can proton therapy reduce radiation-related lymphopenia in glioblastoma?Neuro-oncology · 2021Article
- Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.Medical sciences (Basel, Switzerland) · 2021Article
- One-year survival of patients with high-grade glioma discharged alive from the intensive care unit.Journal of neurology · 2021Observational
- Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCorticosteroids are commonly used to alleviate symptoms from cerebral vasogenic edema in glioblastoma (GBM) patients. This study evaluated the impact of overall corticosteroid exposure during chemoradiotherapy (CRT) on acute severe lymphopenia (ASL) and survival outcomes of GBM patients.
methodsGBM patients treated with CRT from 2007 to 2016 were retrospectively analyzed. Overall corticosteroid exposure was estimated as the average daily dexamethasone dose during 6 weeks of CRT. ASL was defined as grade 3 or higher lymphopenia within 3 months of starting CRT. ASL rates, overall survival (OS), and progression-free survival (PFS) were analyzed using Kaplan-Meier method. Multivariable analysis (MVA) was performed using logistic and Cox regression to identify independent predictors of ASL and survival outcomes, respectively.
resultsOf the 319 eligible patients, the median daily dexamethasone use was 2 mg/day. The high-dose dexamethasone cohort (> 2 mg/day) had significantly higher ASL and worse OS than the low-dose dexamethasone cohort: 3-month ASL of 43.7% versus 19.8% (p < 0.003) and median OS of 12.6 months versus 17.9 months (p < 0.001), respectively. On MVA, higher dexamethasone use was independently associated with higher ASL and worse OS, but not worse PFS. A subset analysis of patients with gross-total resection found that higher dexamethasone use was significantly associated with ASL, but not OS.
conclusionIncreased corticosteroid use among GBM patients during CRT appears to be an independent risk factor for developing subsequent ASL. Its apparent association with worse OS may be influenced by other confounding factors and would need to be validated through prospective investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.